Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax(TM)-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses

- Funding to support GMP manufacture of VesiculoVax(TM)-vectored vaccines for Zaire-Ebola virus, Sudan-Ebola virus, and Angola-Marburg virus that will be blended into a single formulation; rapid follow-up Phase 1 clinical trial planned Phase 1 clinical trial of VesiculoVax(TM) Zaire-Ebola virus vaccine funded -BALTIMORE, Md., Oct. 31, 2014 /PRNewswire via COMTEX/ Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense (DoD) through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program (MCS-JVAP), a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine. In addition, the USACC has contracted for clinical evaluation of the VesiculoVax(TM) Zaire-Ebola virus vaccine to me
http://bit.ly/10a1Nq6